Teva Pharmaceutical Industries (NYSE:TEVA) Update / briefing February 17, 2026 08:00 AM ET Company ParticipantsChristopher Stevo - SVP of Investor RelationsEric Hughes - CMOGlenn Santangelo - Managing DirectorJason Gerberry - Managing DirectorMatt Dellatorre - Vice PresidentRichard Francis - CEOUmair Rafat - Senior Managing DirectorConference Call ParticipantsAsh Verma - Stock AnalystDavid Amsellem - Senior Research AnalystDennis Ding - Stock AnalystLes Salewski - Stock AnalystLouise Chen - Wall Street Anal ...

Key Takeaways Madrigal signed an exclusive global licensing deal with Ribo for six preclinical siRNA programs.MDGL will pay $60M upfront, with up to $4.4B in milestones plus tiered royalties on net sales.Madrigal plans FDA filings in 2026 and will test siRNA candidates with Rezdiffra in MASH.Madrigal Pharmaceuticals (MDGL) announced an exclusive global licensing agreement with Suzhou Ribo Life Science Co. Ltd. (Ribo) and its subsidiary, Ribocure Pharmaceuticals AB (Ribocure), covering six preclinical small ...

Company Overview - The company is a multi-platform oncology firm with over 20 ongoing clinical Phase II and Phase III trials [3] Innovation Approach - The presentation aims to discuss the company's unique approach to innovation, including the scientific and medical concepts and their execution [2]

Core Insights - STRATA Skin Sciences, Inc. is focused on expanding its market by pursuing the inclusion of expanded CPT codes for its XTRAC excimer laser treatments, targeting all inflammatory and autoimmune skin conditions, with implementation expected by January 1, 2026 [1][5] - The company emphasizes its strong patent portfolio, which provides intellectual property and market exclusivity for combination therapies, enhancing its competitive position against inferior technologies [2][3] - STRATA's patents are critical for establishing rights around combination therapies that are likely to become standard care for difficult-to-treat dermatologic conditions, positioning the company at the forefront of integrative dermatologic treatment [3][4] Patent and Technology Developments - STRATA holds three key patents related to the use of Excimer laser therapy in combination with systemic drugs, which are essential for addressing limitations in treating severe or systemic skin diseases [3][4] - The patents enable a synergistic therapeutic effect, potentially leading to enhanced treatment responses, prolonged remission, and improved safety by limiting UV exposure to affected areas [4] Market Expansion and Financial Implications - The American Medical Association's approval of updates to CPT codes will expand reimbursement eligibility for XTRAC treatments, effectively tripling the addressable patient population and improving treatment economics for providers and the company [5] - STRATA's partnership program offers a fee per treatment cost structure, which may enhance revenue opportunities and market penetration [7]